CellCept® (Mycophenolate Mofetil)
Lung Transplant Media Stories
PF Clinical Trials
Mycophenolate mofetil for scleroderma–related interstitial lung disease. Although this study does not provide evidence for equivalency to cyclophosphamide, its clear benefit in patient tolerability made MMF the preferred initial treatment in an arena with limited options. The Lancet Respiratory Medicine, 2016 Nov;4(11):e53.
Mycophenolate mofetil (MMF) is an effective and safe option for the management of systemic sclerosis–associated interstitial lung disease (SSc–ILD). In patients with SSc–ILD with declining pulmonary function, MMF therapy was associated with stability for up to 36 months. PubMed, Clin Exp Rheumatol, 03/24/2016.
Scleroderma Lung Study II. This study compares 2 different medications—daily oral cyclophosphamide (CYC) with daily oral mycophenolate mofetil (MMF, also called CellceptTM) in the treatment of scleroderma-related pulmonary fibrosis. There are twelve study centers across the U.S. University of California, Los Angeles. November 2009. (Also see Pulmonary Fibrosis, Cyclophosphamide, and Clinical Trials)
SCLERO.ORG is the world leader for trustworthy research, support, education and awareness for scleroderma and related illnesses, such as pulmonary hypertension. We are a service of the nonprofit International Scleroderma Network (ISN), which is a 501(c)(3) U.S.-based public charitable foundation, established in 2002. Meet Our Team, or Volunteer. Donations may also be mailed to: